OmicsX
innovation INSIGHTS



Global Targeted Protein Degraders 2025

Covers 330 Drug Developers with Strategic Insights

◎ Technologies ◎ Patents ◎ Pipeline ◎ Funding ◎ Deals

World's Largest Coverage - GUARANTEED



Contents

Infographics

Intelligence Snapshot

Targeted Protein Degradation (TPD) Targets in Development Landscape - 2025

Insights on Emerging Targets Diversity in TPD Space

The TPD landscape is rapidly expanding, with diverse molecular targets spanning oncogenic drivers, epigenetic regulators, apoptosis modulators, immune regulators and neurodegenerative disease markers. This report categorizes these targets into eight key clusters, each representing a distinct therapeutic focus area.

Intelligence Snapshot

Company's Profile

Section B 114

☐ *Individual Profiles of 330 Active Targeted Protein Degrader Drug Developer Companies*

Individual Drug Developer Profile includes:

Company Overview
Key Technology Platform
Key TPD Linked Patents
TPD centered Collaborations, Deals & Partnership.
Funding Details

Targeted Protein Degrader Drug Pipeline –Drugs name, its targets, with details of its development for various indications, NCT Number, Degrader Modality.

Management Profile –Address, Contact number, e-mail, Key Management / Decision Maker (CXOs) name and designation, with individual Linked ID and contact emails.

TARGETED PROTEIN DEGRADERS - GLOBAL DISTRIBUTION



Figure A.1 **330 Active Targeted Protein Degraders (TPD) Drug Development Companies present in United States *vs*. Europe *vs*. Asia *vs*. Canada *vs.* Australia.**

Figure A.2 **Individual Country-wise Distribution of Active TPD Oncology Drug Developers in Europe (53 companies) and Asia (128 companies).**

TARGETED PROTEIN DEGRADERS - MOLECULES IN DEVELOPMENT



Figure A.3 ***TPD Drugs in Development*** **- Divison of 572 Active TPD Molecules on the bascis of Degrader Modality.**
PROTAC | Molecular Glue | Degrader Antibody Conjugates | Deubiquitinase | LYTACs | AUTOTACs | Others / Undisclosed



Figure A.4 **Distribution of Clinical (Phase III, II, I), IND & Preclinical / Discovery Stage TPD Drug Developers.** *(Total 572 Molecules)*



Figure A.5 **Top 12 TPD Targets in Development.**
Report covers 572 Molecules against 144 Unique Targets.

TARGETED PROTEIN DEGRADATION - 2025

TOP 10 PHARMACEUTICALS - ASSETS & COLLABORATIONS

	PROTAC Hetrobifunctional	MOLECULAR GLUE	DEGRADER ANTIBODY CONJUGATE	DUBs Deubiquitinase	LYTACs / AUTOTACs
Pfizer	Vepdegestrant Arvinas	TRIANA Biomedicines	Nurix	Mission Therapeutics	
Johnson&Johnson Innovative Medicine	VantAI	Odyssey Therapeutics			
abbvie	Plexium Calico LifeScience	ABBV-101 *(Inhouse)*	*(Inhouse)*	Mission Therapeutics	ALIA-1758 *(acquired)*
MERCK	Amphista	Proxygen	C4 Therapeutics	Almac Discovery	
Roche	R07656594 GDC-2992 Genentech	Monte Rosa Therapeutics	Genentech	RG6614 KSQ-4279 KSQ Therapeutics	Chugai
AstraZeneca	Pinetree Therapeutics	Francis Crick Institute			
NOVARTIS	JSB462 ARV-766 Arvinas	ITU512 DKY709 Monte Rosa Therapeutics	*(Inhouse)*		*(Inhouse)*
Bristol Myers Squibb™	CC-94676 Amphista	Iberdomide Mezigdomide Golcadomide + 2 more	BMS-986497 ORM-6151 Orum Therapeutics	Ubiquigent	
SANOFI	SAR444656 Nurix Therapeutics	Kymera Therapeutics			
gsk GlaxoSmithKline	Kymera Therapeutics	*(Inhouse)*			

■ MULTIPLE COLLABORATIONS

DRUG Collaborator — Clinical Stage Program

DRUG Collaborator — Preclinical Stage Program

DRUG Collaborator — Discovery Stage Program

As of Jan 2025, the top 10 pharmaceutical companies were developing 36 TPD molecules. In total, 572 TPD molecules are in active development, including 114 in clinical stages, 26 in IND stages, and 432 in preclinical stages.

Section A

330

Targeted Protein Degraders

Intelligence Snapshot

TARGETED PROTEIN DEGRADATION (TPD) DRUG DEVELOPER'S KEY PATENTS - 2025

Drug Developer's TPD Linked Patent Details (*184 Companies | 337 Patents*) Table No. A.7

No.	Company Name	Key TPD Linked Patents (Title)	Patent Number	Date
1.	76Bio, Inc.	Developing dual-specific bifunctional polypeptides that induce degradation of a biological target through the cellular proteasome mechanism.	WO2024081913A1	Oct-23
		Bifunctional fusion proteins for ubiquitin-mediated degradation.	WO2023215839A1	May-23
2.	Accutar Biotechnology, Inc	Glutarimide-containing pan-KRAS-mutant degrader compounds and uses thereof	US20240294527A1	Nov-2022
		Heterocyclic compounds as e3 ligase inhibitors	WO2024073502A1	Sep-2022
3.	Adlai Nortye Limited	Cyclin k degradation agent.	WO2023025225A1	Aug-22
4.	AevisBio, Inc.	Novel pomalidomide derivatives and preparation method therefor	WO2023249470A1	Jun-23
		Specific Compound Binding for Target Protein and Target Degrader, Pharmaceutical Compositions Comprising the Same, and the Use thereof	KR20240141067A	Mar-23
5.	Almac Discovery Ltd.	Piperidine derivatives as inhibitors of ubiquitin specific protease 7.	AU2017346516B2	Oct-2016
		Heterocyclic compounds as ubiquitin specific protease 7 inhibitors.	WO2023139241A1	Jan-2022
6.	Amphista Therapeutics Limited	Targeted protein degradation of KRAS(G12D).	GB202208860D0	Jun-2022
		Targeted protein degradation of EGFR	GB202208888D0	Jun-2022
7.	Angiex, Inc.	Degrader-antibody conjugates and methods of using same.	WO2021195598A2	Mar-2021
8.	AnHorn Medicines Co., Ltd.	Bifunctional compound and pharmaceutical composition	WO2024002206A1	Jun-2022
9.	Apertor Pharmaceuticals, Inc.	Small molecule compounds	US20240350463A1	Jun-2022
		Disclosed herein are pharmaceutical compositions comprising biosynthetic allosteric mTOR inhibitors	US20230104503A1	Jun-2021
10.	Aprinoia Therapeutics, Inc.	Compounds for degrading tau protein aggregates and uses thereof	WO2021097243A1	Nov-2020
		Compounds for degrading α-synuclein aggregates and uses thereof	US11291732B1	May-2021
11.	Aptadegrad S.L.	Dna aptamer conjugates recognizing and degrading coronavirus proteins	WO2024003300A1	Jun-23
12.	Arrakis Therapeutics, Inc.	RNA degraders and uses thereof	WO2024112918A1	Nov-2022
13.	Arvinas, Inc.	Indazole based compounds and associated methods of use.	US20240360152A1	May-2024
		Use of an Androgen Receptor degrader PROTAC for the treatment of prostate	WO2024220926A1	Apr-2023

TARGETED PROTEIN DEGRADATION (TPD) CLINICAL & IND STAGE PIPELINE COVERAGE - 2025

Clinical-Stage Targeted Protein Degraders (TPDs) Molecules in Development

(81 Companies Developing 110 Molecules)

Table No. A.8

No.	Company Name	Country	Molecule Name	Target	Phase	Indication	NCT Number	Degrader Modality
1.	Bristol Myers Squibb	United States	Mezigdomide / CC-92480	IKZF1/ 3	III	R/R Multiple Myeloma	NCT05552976	CELMoD (Molecular Glue)
			Iberdomide / CC220	IKZF1/ 3	III	Multiple Myeloma	NCT04975997	CELMoD (Molecular Glue)
2.	Pfizer, Inc.	United States	Vepdegestrant / ARV-471	ER	III	Breast Cancer	NCT05654623	PROTAC
3.	AstraZeneca	United Kingdom	Camizestrant / AZD9833	ER	III	ER+/HER2- Advanced Breast Cancer	NCT04964934	SERD
4.	Eli Lilly and Company	United States	Imlunestrant / LY3484356	ER	III	Metastatic Breast Cancer	NCT04975308	SERD
5.	Roche Ltd.	Switzer-land	Giredestrant / GDC-9545	ER	III	Breast Cancer	NCT06065748	SERD
6.	Eisai Inc	Japan	E7820	RBM23/39	II	Acute Myeloid Leukemia	NCT05024994	Molecular Glue
7.	Innovo Therapeutics	United States	INV-001	HSP47	II	Scar	NCT05838833	Targeted Protein Degradation
8.	Kintor Phar-maceutical Limited	China	GT20029	AR	II	Androgenetic Alopecia	NCT06692465	Heterobifunctional Degrader
9.	Kymera Therapeutics Inc.	United States	KT-474 / (SAR444656)	IRAK4	II	Atopic Dermatitis	NCT06058156	Monovalent Degrader
					II	Hidradenitis Sup-purativa	NCT06028230	
10.	MISSION Therapeutics	United Kingdom	MTX652	USP30	II	Heart Failure		DUB
			MTX325	USP30	II	Parkinson's Dis-ease	IS-RCTN20898392	DUB
11.	Sanofi SA	France	SAR444656	IRAK4	II	Atopic Dermatitis	NCT06058156	Chimeric Degrader
					II	Hidradenitis Suppurativa	NCT06028230	
12.	AbbVie Inc.	United States	ABBV-101	BTK De-grader WT & C481S	I	B-Cell Malignancies	NCT05753501	Molecular Glue
13.	Accutar Biotechnology Inc.	United States	AC0176	Androgen Receptor	I	Prostate Cancer (mCRPC)	NCT05241613	Heterobifunctional Degrader
			AC0682	Estrogen Receptor	I	Metastatic ER+ Breast Cancer	NCT05080842	Heterobifunctional Degrader
			AC0699	Estrogen Receptor	I	Breast Cancer	NCT05654532	Heterobifunctional Degrader
			AC0676	BTK De-grader (WT & C481S)	I	B-Cell Malignancies	NCT05780034	Heterobifunctional Degrader

Targeted Protein Degradation Targets Development Landscape - 2025

Targeted Protein Degradation (TPD) Targets can be Grouped in Eight Major Clusters based on their Function and Disease Indication -

1.1 ***Oncogenic Signaling and Kinases*** -

These targets regulate critical pathways involved in cancer progression, proliferation, and survival.

1.2 ***Epigenetic and Transcriptional Regulators*** -

Focus on modulating gene expression and chromatin remodeling for various diseases.

1.3 ***Apoptosis and Protein Stability Regulators*** -

Key modulators of programmed cell death and protein homeostasis

1.4 ***Structural and Metabolic Pathway Modulators*** -

Targets involved in oxidative stress responses, intracellular metabolism and extracellular matrix remodeling.

1.5 ***Neurodegenerative and Rare Disease Targets*** -

Proteins implicated in neurodegeneration and rare genetic disorders.

1.6 ***Immune Modulation and Inflammatory Disease Targets*** -

Targets involved in immune regulation and inflammation.

1.7 ***Viral and Pathogen Associated Targets*** -

Targets to address viral and bacterial infections.

1.8 ***Emerging and Miscellaneous Targets*** -

Unconventional or niche targets expanding the scope of TPD.

CLUSTER 1 : ONCOGENIC SIGNALLING AND KINASES (*163 companies*)

Key Focus Areas: Growth factor receptors, oncogenic kinases, cell cycle regulators, signaling pathway modulators, and hormone-driven cancer targets.

TPDs are emerging as a breakthrough approach to **overcome therapy resistance** and drive tumor regression in various cancers. This cluster focuses on targets that fuel **oncogenic signaling, regulate cell proliferation and modulate immune escape mechanisms**, offering novel avenues for precision oncology.

Key Target Groups:

- **Cluster 1.1 Growth Factor Receptors** : EGFR (including resistant mutants like C797S), HER2, FGFR3 and c-MET. ***(16 Molecules)***
- **Cluster 1.2 Oncogenic Kinases** : BRAF (V660X), KRAS (G12C/D), NRas, BTK, CK1α, FLT3, ERK5, Mnk1/2, BCR-ABL and ALK. ***(64 Molecules)***
- **Cluster 1.3 Cell Cycle Regulators :** CDK4/6, CDK7/9, Cyclin D1, Cyclin K, PLK1, WEE1 and CCNK x CDK12. ***(27 Molecules)***
- **Cluster 1.4 Signaling Pathway Kinases**: ATR, AXL, ALK, RAF1, MEK-RAF, PI3K alpha, ILK, TrkA. ***(16 Molecules)***
- **Cluster 1.5 Immune Signaling Modulators:** IRAK-M, FAK, STAT3, PKC-θ, SHP2, Grk2, IL-4Rα and TRIB1. ***(11 Molecules)***
- **Cluster 1.5 Hormone Receptors in Cancer - Androgen Receptor (AR)** : Crucial in prostate cancer progression. **Estrogen Receptor (ER) and Selective Estrogen Receptor Degraders (SERDs)** : Key regulators in HR+ breast cancer. ***(54 Molecules)***

Market Outlook:

With multiple **TPD-based candidates advancing through clinical trials**, targeting ***oncogenic kinases, hormone receptors*** and ***immune modulators*** represents **one of the most dynamic areas** in precision oncology. The **degradation-first** approach is reshaping cancer therapy, addressing resistance mechanisms, and expanding treatment options for hard-to-treat cancers.

CLUSTER 1.1 : Growth Factor Receptors (*16 Molecules*)

Table No. D.1

TARGETS : EGFR (including C797S-resistant mutants), HER2, FGFR3, C-MET

No.	Company Name	Country	Molecule Name	Target	Phase	Indication	Degrader Modality
1.	C4 Therapeutics Inc	United States	CFT8919	EGFR, L858R	I	Non Small Cell Lung Cancer	BiDAC
2.	Haisco Pharmaceutical Group Co., Ltd.	China	HSK40118	EGFR	I	Non-small cell lung cancer	Heterobifunctional
3.	Jing Medicine Technology (Shanghai), Ltd.	China	HJ-002-03	EGFR C797S	I	Non-Small Cell Lung Cancer	Heterobifunctional
4.	Betta Pharmaceuticals Co., Ltd.	China	CFT8919	EGFR	IND	Non Small Cell Lung Carcinoma	BiDAC
5.	Epibiologics, Inc.	United States	EPI-326	EGFR	IND	Non-Small Cell Lung Carcinoma	Degrader Antibody Conjugates (DACs)
6.	GlueTacs Therapeutics	China	GT868	EGFR	Preclinical	Non-small cell lung cancer	GLUETAC Degrader
7.	Bridge Biotherapeutics, Inc.	South Korea	BBT-176	EGFR	Preclinical	Oncology	Heterobifunctional
8.	HK inno.N Corporation	South Korea	Undisclosed	EGFR	Preclinical	Oncology	Heterobifunctional
9.	J2H Biotech, Inc.	South Korea	J2H-2002	EGFR	Preclinical	Non-Small Cell Lung Cancer	Heterobifunctional
10.	Polymed Biopharmaceuticals	China	HPB-001	EGFR	Preclinical	Neoplasms	Heterobifunctional
11.	TYK Medicine, Inc.	China	TY-3200	EGFR	Preclinical	Solid Tumors	Heterobifunctional
12.	Orum Therapeutics Inc.	South Korea	ORM-5029	Her2	I	HER2-positive Breast Cancer	Molecular Glue
13.	Chengdu Fendi Pharmaceuticals Co., Ltd.	China	FD-004	HER2	Preclinical	Oncology	Degrader Antibody Conjugates
14.	Blueprint Medicines Corporation	United States	Undisclosed	FGFR3	Preclinical	Oncology	Heterobifunctional
15.	Pierre Fabre Laboratories	Japan	PFL-002/ VERT-002	c-MET	I/II	Non-Small Cell Lung Cancer	Degrader Antibody Conjugates
16.	Oncozen Co., LTD.	South Korea	OZ-003	cMET	Discovery	Non Small Cell Lung Cancer	Heterobifunctional

TARGETED PROTEIN DEGRADATION (TPD) FUNDING & DEALS LANDSCAPE - 2025

Targeted Protein Degradation Drug Development Companies - Private Financing 2023 - 2024

Table No. A.13

No.	Company Name	Country	Funding Amount	Funding Round	Month / Year	Key Investors in the Round
1.	76Bio, Inc.	*United States*	$12.2 Mn	Undisclosed	Feb-23	Two River Group Holdings
2.	A-Alpha Bio, Inc.	*United States*	$14.5 Mn	Grant	May-24	Department of Defense
			$22.4 Mn	Series A2	Jul-23	Xontogeny Ventures, Madrona
3.	AevisBio, Inc.	*South Korea*	600 Mn KRW	Grant	Jan-23	National Research Foundation of Korea
4.	AIGEN Sciences Inc.	*South Korea*	12 billion KRW (US $8.8 Mn)	Series A	Oct-24	Quad Investment Management. Medytox Venture Investment, Premier Partners, K2 Investment Partners, Scale Up Partners
5.	AnHorn Medicines Co., Ltd.	*Taiwan*	$10 Mn	Series A	Apr-23	TaiAn Technologies, Industrial Technology Investment Corporation, Hong Tai Electric Industrial, Black Marble Capital Management, Mega Venture Capital and Sunplus Technology.
6.	Aurigene Oncology Limited	*India*	₹6,500 Mn	Undisclosed	May-24	Dr. Reddy's Laboratories
7.	Automera Pte. Ltd	*Singapore*	$16 Mn	Series A	Sep-23	ALSP and ClavystBio, EDBI, Xora Innovation
8.	Avilar Therapeutics, Inc.	*United States*	$75 Mn	Seed	Feb-23	RA Capital Management, Sanofi Ventures, Medical Excellence Capital (MEC), Astellas Venture Management (AVM).
9.	Biolexis Therapeutics, Inc.	*United States*	$10 Mn	Series A	Nov-23	Clarke Capital
10	Chengdu Zeling Biomedical Technology Co. Ltd.	*China*	106.5 Mn Yuan	Series B	Nov-23	Precision Medicine Industry Innovation Fund (managed by Chengdu Science and Technology Venture Capital) and Huajin Capital, Ceyuan Capital, Shengzhong Investment.
11.	ChomiX Biotech Co., Ltd.	*China*	N/A	Pre A Series	May-23	TigerYeah Capital Tsinghua Innovation Ventures Morning Spring Venture.
12.	ConfometRx, Inc.	*United States*	N/A	Grant	Sep-23	SBIR
			N/A	Grant	Jul-23	SBIR
13.	Cullgen, Inc.	*United States*	$35Mn	Series C	May-23	AstraZeneca-CICC Venture Capital Partnership, Sincere Capital, Voyagers Capital, Wuxi Capital Group and GNI Group Ltd.
14.	Degrome Therapeutics, Inc.	*United States*	$0.5 Mn	Grant	Sep-24	National Institute on Aging
15.	Degron Therapeutics, Inc.	*China*	$34.5 Mn		Dec-24	Undisclosed

Targeted Protein Degradation Drug Development Companies Research Collaboration with Non Profit Organizations (*19 Deals*)

Table No. A.16

No.	Early Stage Onco Drug Developer	Partner Company	Month	Description
1.	BPGbio, Inc.	University of Oxford	Oct-24	BPGbio and University of Oxford enter into strategic collaboration focused on breakthrough E2- based Protein Degradation research in Oncology and CNS diseases.
2.	Livzon Pharmaceutical Group, Inc.	Shanghai Institute of Organic Chemistry and the University of Michigan	Sep-24	Scientists at Livzon Pharmaceutical Group Inc., Shanghai Institute of Organic Chemistry and the University of Michigan have identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety covalently bound to a cyclin-dependent kinase 12 (CDK12) and 13 (CDK13) targeting moiety through a linker reported to be useful for the treatment of cancer.
3.	Livzon Pharmaceutical Group, Inc.	State Key Laboratory of Chemical Biology and International Cooperative Laboratory of Traditional Chinese Medicine	Dec-23	Livzon Pharmaceutical collaborated with State Key Laboratory of Chemical Biology and International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE) have discovered LHF418 as a new potent SOS1 PROTAC degrader.
4.	Beactica AB	National Center for Advancing Translational Sciences (NCATS)	Sep-23	Beactica Therapeutics signed research collaboration with the National Center for Advancing Translational Sciences (NCATS), to evaluate Beactica's proprietary targeted TEAD degraders efficacy in disease-relevant preclinical models. NCATS to also map systematically the drug-combination landscape for selected preclinical candidates by performing a highthroughput drug-combination screen.
5.	Astrazeneca Plc	Francis Crick Institute and Imperial College London	May-23	AstraZeneca partnered with the Francis Crick Institute and Imperial College London to advance the discovery of new molecular glues aimed at treating a range of diseases. This partnership recieved nearly £22.5 Mn in funding through Prosperity Partnership grant from the Engineering and Physical Sciences Research Council (EPSRC) and from AstraZeneca.
6.	Genoscience Pharma	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.	Apr-23	Genoscience Pharma sign a new research agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., the wholly owned subsidiary and technology transfer company of the Hebrew University of Jerusalem. The collaboration aims to expand the development of PROTAC technology on investigative Genoscience agents, which can increase the potency and selectivity of small molecule drugs and overcome cancer resistance to existing therapies.
7.	Nexo Therapeutics, Inc.	MD Anderson	Jul-23	MD Anderson and Nexo Therapeutics signed strategic research collaboration to work together from discovery through investigational new drug-enabling studies to accelerate development of small-molecule therapies for patients with limited treatment options.
8.	Manhattan Biosolutions LLC	Wisconsin Alumni Research Foundation (WARF)	May-23	Manhattan BioSolutions entered into an exclusive option agreement with the Wisconsin Alumni Research Foundation (WARF) for the innovative pan-RNA degrader technologies (pRNAD) in oncology.
9.	Livzon Pharmaceutical Group, Inc.	International Cooperative Laboratory of Traditional Chinese Medicine Modernization and the State Key Laboratory of Bioorganic & Natural Products	Feb-23	Livzon Pharmaceutical collaborated with the International Cooperative Laboratory of Traditional Chinese Medicine Modernization and the State Key Laboratory of Bioorganic & Natural Products Chemistry to advance the discovery of AXL degraders with Improved Potencies in Triple-Negative Breast Cancer.
10.	Bridge Biotherapeutics, Inc.	Scripps Research	Aug-22	Biotherapeutics and Scripps Research launch research collaboration in the fields of covalent targeting and chemical biology. The company aims to develop novel therapeutics for high-value targets in the oncology and immunology space and believes that innovative reactive group chemistries combined with proteomics can facilitate this objective. Bridge seeks to discover proprietary, tunable ligands for covalent drug development and protein degrader applications.

Section B

330 Targeted Protein Degraders Profiles

AbbVie, Inc.

Diversified

1 North Waukegan Road
North Chicago, IL 60064,
United States

www.abbvie.com
-
+1 847-932-7900

Founded: 2013
Employee: 10,000+
Ownership: Public

Highlights

- AbbVie (ABBV : NYSE) is actively engaged in the field of targeted protein degradation (TPD), focusing on developing innovative therapies across various therapeutic areas, including oncology and neuroscience. Their research involves designing protein degraders that bind to specific proteins and trigger their degradation via the proteasomal pathway.
- AbbVie's internal research teams have been exploring **Degradomers**—molecules that degrade proteins within cells. Their work focuses on building a sustainable and scalable platform for protein degradation across different therapeutic areas, including oncology, immunology, and neurology.
- ***Key Patents*** - 1. ANTI-HUMAN CD33 BET DEGRADER ANTIBODY-DRUG CONJUGATES. - US20250000993A1 (Jan 2025).
- Pyrimidines for degrading Bruton's tyrosine kinase - US12172992B2 (*Dec 2024*)
- **TPD Linked Deals & Collaborations -** In Oct 2024, AbbVie acquired Aliada Therapeutics for $1.4 billion, aiming to bolster its Alzheimer's treatment portfolio. This acquisition focuses on Aliada's experimental antibody therapy, ALIA-1758, designed to degrade amyloid beta plaques in the brain, highlighting AbbVie's commitment to advancing TPD in neurological conditions.
- In Aug 2022, Plexium and AbbVie entered into an exclusive strategic collaboration to develop and commercialize novel Targeted Protein Degradation (TPD) therapeutics for neurological conditions. Under the terms, Plexium will run preclinical research for the companies' targets. Once completed, AbbVie will have the option to pick programs for more research and development. Further financial details remains undisclosed.
- In Dec 2020, Frontier Medicines Corporation and AbbVie signed multi-year collaboration to utilize Frontier's proprietary chemoproteomics platform to identify small molecules for programs directed to novel E3 ligases and certain oncology and immunology targets. Under the terms, Frontier received $55 Mn as an upfront and is eligible to receive additional milestone payments. In addition, AbbVie will reimburse Frontier's R&D costs through defined stages of pre-clinical development. AbbVie will assume full responsibility for global development and commercialization activities and costs for the programs. Frontier will be eligible to receive milestone payments that could potentially exceed $1 billion, in addition to royalty payments on commercialized products.
- In Nov 2018, Mission Therapeutics and AbbVie signed collaboration to develop DUBs molecules targeting Alzheimer's and Parkinson's Disease. No financial details have been disclosed. The collaboration does not include any of Mission's lead DUB programs including USP30 and USP10.
- ***AbbVie - Calico Life Sciences (an Alphabet Company) Collaboration -:-*** In 2014, AbbVie and sign Calico Life Science, signs multi year collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. Under this collaboration, the two companies produced more than two dozen early-stage programs addressing disease states across oncology and neuroscience.
- In 2018, both companies extended their collaboration to reshape their further development responsibilities. Under the terms, Calico will be responsible for research and early development until 2022 and will advance collaboration projects through Phase 2a through 2027. AbbVie will continue to support Calico in its early R&D efforts and, following completion of Phase 2a studies, will have the option to manage late-stage development and commercial activities. Both parties will share costs and profits equally. AbbVie and Calico will each commit to contribute an additional $500 Mn to the collaboration.
- As a part of this collaboration, Abbvie Inc. and Calico Life Sciences LLC has led to the development of proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) and/or PTPN1B. They are reported to be useful for the treatment of cancer, type 2 diabetes and nonalcoholic steatohepatitis (NASH).
- Abbvie is in research collaboration with Germany based PROXIDRUGS, which has developed a versatile assay, screening and molecular profiling platforms for the identification and characterisationof proximity-inducing molecules, with a particular focus on molecular glues for the treatment of neurological diseases, cancer and other disorders.

Targed Protein Dregrader Pipeline

Name	Target	Phase	Indication	NCT Number	Degrader Modality
ABBV-101	BTK	I	B-cell Malignancies	NCT05753501	Molecular Glue
ALIA-1758	Amyloid beta	Preclinical	Alzheimer's Diseases		LYTAC

Targed Protein Dregrader Pipeline (In Collaboration)

Partner	Program	Target	Phase	Indication	NCT Number	Degrader Modality
Mission Therapeutics	Confidential	Undisclosed	Preclinical	Alzheimer's Diseases	-	DUB
Mission Therapeutics	Confidential	Undisclosed	Preclinical	Alzheimer's Diseases	-	DUB

Drug Descriptions

- ABBV-101: A small molecule degrader targeting Bruton's tyrosine kinase (BTK), currently in Phase 1 clinical trials for the treatment of B-cell malignancies.
- ALIA-1758: An experimental bispecific antibody therapy designed to degrade amyloid beta plaques in the brain, aimed at treating Alzheimer's disease.
- ABBV 484 is a small IO molecule, it is being studied in participants with locally advanced or metastatic tumors.
- Calico is responsible for research and early development and will advance collaboration projects into Phase 2a, including ABBV-CLS-579. AbbVie will continue to support Calico in its early R&D efforts and, following completion of Phase 2a studies, will have the option to manage late-stage development and commercial activities.

Corporate Profile

Michael E. Severino, *Vice Chairman and President* LinkedIn profile

Thomas Spalding, *Vice President, Oncology* *thomas.spalding@abbvie.com* LinkedIn profile

Accutar Biotechnology, Inc.

Cancer

8 Clarke Drive Suite 4,
Cranbury, NJ 08512
United States

www.accutarbio.com
corporate@accutarbio.com
+1 929-262-0884

Founded: 2015
Employee: 11-50
Ownership: Private

Highlights

- Accutar Biotechnology, Inc. is a clinical stage biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery to develop orally bioavailable, chimeric degrader molecules targeting cancer.
- ***Key Technologies*** -PPI-TAC (Protein-Protein Interaction Targeting Chimera) platforms creates chimeric molecules to precisely target and modulate protein-protein interactions (PPIs), offering a novel approach for diseases like cancer. By bridging or disrupting specific PPIs, these chimeras selectively degrade or alter disease-related proteins, advancing targeted therapies.
- ***Key Patents*** - 1. Glutarimide-containing pan-KRAS-mutant degrader compounds and uses thereof. - US20240294527A1. (Dated : 2022-11-30)
- 2. Heterocyclic compounds as e3 ligase inhibitors. - WO2024073502A1. (Dated : 2022-09-28)
- ***TPD Linked Deals & Collaborations*** - In Nov 2023, Accutar and Evommune, Inc. collaborate for the discovery of inflammatory diseases by leverage Accutar's AI drug discovery platform. The financial details involved were not disclosed.
- ***Funding*** - In Aug 2021, Accutar Biotech raised undisclosed funds in a new round of funding from Yunfeng Capital, Coatue, and 3W Healthcare Fund. Since inception, Accutar Biotech has raised nearly US$100 Mn to support the advancement of its artificial intelligence (AI)-empowered platform and the expansion of proprietary drug pipeline.

Targed Protein Dregrader Pipeline

Name	Target	Phase	Indication	NCT Number	Degrader Modality
AC0176	AR	I	Prostate Cancer (mCRPC)	NCT05241613	Heterobifunctional
AC0682	ER alpha	I	Metastatic ER+ Breast Cancer	NCT05080842	Heterobifunctional
AC0699	ER alpha	I	Breast Cancer	NCT05654532	Heterobifunctional
AC0676	BTK (WT & C481S)	I	B-Cell Malignancies	NCT05780034	Heterobifunctional
Undisclosed	Undisclosed (Multiple Novel E3 Ligases)	Preclinical	Cancer	-	Heterobifunctional

Drug Descriptions

- AC0176 is an investigational orally bioavailable, Heterobifunctional (PROTAC) degrader of AR for the potential treatment of prostate cancers.
- In preclinical studies, AC0176 demonstrated potent and selective AR protein degradation with broad coverage of AR mutants, favorable pharmacological properties, as well as promising anti-tumor activity in animal models.
- AC0682 is an investigational orally bioavailable, Heterobifunctional (PROTAC) degrader of ERα for the potential treatment of ER-positive breast cancers. ERα is a hormone-regulated transcription factor that plays a critical role in breast cancer initiation and proliferation, and nearly 80% of breast cancers express ERα.
- AC699 is a potent and selective orally bioavailable, chimeric degrader of estrogen receptor (ER) α, and offers a potential new breast cancer treatment option based on a differentiated mechanism of action as compared to fulvestrant and novel SERDs with deeper ERα degradation.
- AC0676, an orally bioavailable, chimeric degrader molecule designed to target and degrade Bruton's Tyrosine Kinase (BTK) with high potency, selectivity, and broad mutant coverage.

Corporate Profile

Jie Fan, *Founder & Chief Executive Officer* *jiefan@accutarbio.com* **Linked** in profile
Wei He, *Chief Scientific Officer* *weihe@accutarbio.com* **Linked** in profile

Contact Us

reports@omicsx.com
2760 Link Road, Industrial Area,
AGRA 282006, INDIA

Phone : (+91) 562 2970444

Mobile : (+91) 9760 241 412

Website : www.omicsx.com